

U.S. Patent Application No. 10/523,572
Amendment dated November 21, 2007
Reply to Office Action of August 24, 2007

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (Currently amended) A method for preparing platelet-rich plasma from blood, comprising: adding water soluble polyamino acid(s) and/or pharmacologically acceptable salts thereof to the blood thereby accelerating the sedimentation of the red blood cells in the blood; and separating the sedimented red blood cells and the platelet-rich plasma ~~a step of agglutinating and sedimenting red blood cells in a selective and accelerative manner from blood, wherein the water soluble polyamino acid is a homopolymer.~~
2. (Original) The method for preparing platelet-rich plasma according to claim 1, wherein the blood is whole blood obtained by blood collection.
- 3-4. (Canceled)
5. (Currently amended) The method for preparing platelet-rich plasma according to claim 1 3, wherein the polyamino acid or pharmacologically acceptable salts thereof ~~water-soluble polymer compound~~ is a polymer compound having a molecular weight of 1,000 - 5,000,000.
6. (Currently amended) The method for preparing platelet-rich plasma according to claim 1 3, wherein the polyamino acid or pharmacologically acceptable salts thereof ~~water-soluble polymer compound~~ is added in an amount of 0.0001 - 10 w/v% with respect to a blood volume.

U.S. Patent Application No. 10/523,572
Amendment dated November 21, 2007
Reply to Office Action of August 24, 2007

7. (Canceled)

8. (Currently amended) The method for preparing platelet-rich plasma according to claim 1 ~~7~~, wherein the polyamino acid(s) ~~acid~~ is at least one kind selected from the group consisting of polyglutamic acid, polyaspartic acid, polyhistidine, and polyasparagine.

9. (Currently amended) The method for preparing platelet-rich plasma according to claim 1 ~~7~~, wherein the amino acids and/or pharmacologically acceptable salts thereof, which ~~are formed~~ form the polyamino acid, are selected from the group consisting of glutamic acid, aspartic acid, histidine, ~~and~~ asparagine, and ~~or~~ pharmacologically acceptable salts of these.

10. (Currently amended) The method for preparing platelet-rich plasma according to claim 9, wherein at least 20% of the amino acids which the polyamino acid comprises is glutamic acid and/or aspartic acid, or pharmacologically acceptable salts thereof.

11. (Currently amended) The method for preparing platelet-rich plasma according to claim 9, wherein the polyamino acid is an acidic polyamino acid.

12. (Withdrawn) The method for preparing according to claim 7, wherein the acidic polysaccharide and/or pharmacologically acceptable salt thereof is at least one kind selected from the group consisting of dextran derivatives, glycosaminoglycan, cellulose derivatives, chitosan derivatives, galacturonic acid, and alginic acid, or pharmacologically acceptable salts thereof.

U.S. Patent Application No. 10/523,572
Amendment dated November 21, 2007
Reply to Office Action of August 24, 2007

13. (Withdrawn) The method for preparing according to claim 7, wherein the acidic polysaccharide and/or pharmacologically acceptable salt thereof is hyaluronic acid or a pharmacologically acceptable salt thereof.
14. (Withdrawn) The method for preparing according to claim 7, wherein the vinyl polymer is at least one kind selected from compounds including an acidic polymer or a pharmacologically acceptable salt thereof.
15. (Withdrawn) A platelet-rich plasma prepared by the method according to claim 1.
16. (Withdrawn) An accelerator of tissue and/or organ repair, which comprises the platelet-rich plasma according to claim 15.
17. (Withdrawn) An accelerator of tissue and/or organ repair, an additive for bone augmentation in the periphery of a dental implant, an additive for use when transplanting bone or artificial bone to a bone defect site, a wound healing accelerator, an accelerator of tissue repair after therapy or treatment for plastic and/or cosmetic purposes, a therapeutic agent for dermatosis, a therapeutic agent for cutaneous ulcers, an agent for nerve tissue repair and/or an agent for postoperative tissue repair which comprise the platelet-rich plasma according to claim 15.
18. (Withdrawn) A therapeutic method or a treatment method for any of the following, which

U.S. Patent Application No. 10/523,572
Amendment dated November 21, 2007
Reply to Office Action of August 24, 2007

comprises a step of administering the platelet-rich plasma according to claim 15:

- 1) bone augmentation in the periphery of a dental implant;
- 2) dermatosis;
- 3) tissue repair for plastic and/or cosmetic purposes;
- 4) repair of a bone defect site;
- 5) nerve tissue repair; and
- 6) postoperative tissue repair.

19. (Withdrawn) A reagent or a reagent kit for preparing platelet-rich plasma that contains at least one kind of the components described below from among water-soluble polymer compounds used for preparing platelet-rich plasma by a method comprising a step of adding a water-soluble polymer compound to blood:

- 1) a polyamino acid comprising amino acids and/or pharmacologically acceptable salts of amino acids;
- 2) an acidic polysaccharide and/or pharmacologically acceptable salt thereof; and
- 3) a vinyl polymer.

20. (Withdrawn) An instrument for preparing platelet-rich plasma by adding at least one kind of the components of water-soluble polymer compounds described below to blood:

- 1) a polyamino acid comprising amino acids and/or pharmacologically acceptable salts of amino acids;
- 2) an acidic polysaccharide and/or pharmacologically acceptable salt thereof; and
- 3) a vinyl polymer.

U.S. Patent Application No. 10/523,572
Amendment dated November 21, 2007
Reply to Office Action of August 24, 2007

21. (Withdrawn) A kit for preparing platelet-rich plasma, which comprises the reagent or the reagent kit according to claim 19 and an instrument for preparing platelet-rich plasma by adding at least one kind of the components of water-soluble polymer compounds described below to blood:

- 1) a polyamino acid comprising amino acids and/or pharmacologically acceptable salts of amino acids;
- 2) an acidic polysaccharide and/or pharmacologically acceptable salt thereof; and
- 3) a vinyl polymer.